Acute respiratory distress syndrome Acute respiratory distress syndrome
Conditions
Interventions
Incidence of death and invasive mechanical ventilation from the start of hydrogen administration to 10 days
Sponsors
Nakao Atsunori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are 20 years of age or older at the time of consent 2. Patients diagnosed with acute respiratory distress syndrome 3. Patients for whom high-flow nasal cannula is indicated 4. Patients who can perform hydrogen gas inhalation therapy within 48 hours after diagnosis of acute respiratory distress syndrome 5. Patients from whom written consent can be obtained either directly or through a surrogate decision maker.
Exclusion criteria
Exclusion criteria: 1. Patients with traumatic acute respiratory distress syndrome. 2. Patients who have received hydrogen gas inhalation within 1 month. 3. Patients with endotracheal intubation tube or tracheostomy tube. 4. Patients with bilateral nasal obstruction or nasal cavity damage. 5. Patients with severe chronic liver dysfunction equivalent to Grade C in the Child-Pugh classification. 6. Patients with chronic renal dysfunction requiring dialysis (Newly started hemodialysis due to the present illness is not treated as an exclusion criterion). 7. Patients who have started or will start invasive mechanical ventilation or ECMO. 8. Patients with chronic lung disorders requiring home oxygen therapy (Newly started oxygen therapy due to the present illness is not treated as an exclusion criterion). 9. Patients not tolerant to high-flow nasal cannula. 10. Patients with or suspected of having cancer. 11. Women who are pregnant or possibly pregnant. 12. Women who are breastfeeding. 13. Patients who have received other research or investigational drugs within the past 3 months. 14. Other patients who the investigator has determined to be ineligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of death and invasive mechanical ventilation from the start of hydrogen administration to 10 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of related adverse event from the start of hydrogen administration to 10 days 2. Respiratory function assessment: AaDO2, PaCO2, respiratory frequency, P/F ratio, Borg index 3. Inflammation assessment: WBC level, body temperature, IL-6, CRP, procalcitonin 4. Medical costs, ICU stay, duration of oxygen therapy requirement, duration of invasive mechanical ventilation. | — |
Contacts
Public ContactToshiyuki Aokage
Okayama University Hospital
Outcome results
None listed